A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Latest Information Update: 25 Dec 2025
At a glance
- Drugs AZD-1163 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms LaunchPAD-RA
- Sponsors AstraZeneca
Most Recent Events
- 18 Dec 2025 Status changed from not yet recruiting to recruiting.
- 17 Dec 2025 New trial record